[Recommendations for therapy, chemoprevention and chemoprophylaxis of tuberculosis in adults and children. German Central Committee against Tuberculosis (DZK), German Respiratory Society (DGP)].
Several new international recommendations have been published since the German Central Committee against Tuberculosis (DZK) published its recommendations for drug treatment of tuberculosis (TB) in 2001 and for chemoprevention of latent tuberculosis infection (LTBI) in 2004. These international publications have been integrated in the present new recommendations which describe both the treatment of active TB and preventive treatment, pointing out specific adaptations for Germany. Separate sections deal with the current management of mono-, poly-, and multiresistance or drug intolerance, of TB in children, of different forms of extrapulmonary TB, of LTBI and of special situations such as HIV infection, renal or hepatic insufficiency, infection following BCG instillation in bladder cancer or in case of adverse drug reactions. The following aspects differ from the previous recommendations: A three-drug regimen for the so-called fully susceptible minimal TB is no longer recommended in adults. A dosage of 15 mg/kg body weight of ethambutol for adults is regarded as sufficient. Four secondline drugs (supplemented by pyrazinamide, where appropriate) are recommended for multidrug-resistant tuberculosis (MDR-TB). MDR-TB should be treated over a period of at least 20 months, with an injectable drug administered for a minimum of 8 months (initial phase). Ciprofloxacine and ofloxacine are no longer used to treat TB. It is also recommended to offer an HIV test to all TB patients to complement antiretroviral therapy, if necessary, and to adapt the antituberculous therapy accordingly.
Zentrum für Pneumologie, Diakoniekrankenhaus Rotenburg, Wümme. schaberg@diako-online.de
T
T
Schaberg
T
T
Bauer
S
S
Castell
K
K
Dalhoff
A
A
Detjen
R
R
Diel
U
U
Greinert
B
B
Hauer
C
C
Lange
K
K
Magdorf
R
R
Loddenkemper
D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000145:classification*; D002648:Child; D005858:Germany; D006801:Humans; D015272:Pulmonary Medicine / Q000592:standards*; D055502:Secondary Prevention; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*
D000995:Antitubercular Agents